Research programme: HIV maturation inhibitors - Panacos Pharmaceuticals

Drug Profile

Research programme: HIV maturation inhibitors - Panacos Pharmaceuticals

Alternative Names: Next-generation HIV maturation inhibitors - Panacos; Third-generation HIV maturation inhibitors - Panacos

Latest Information Update: 03 Apr 2009

Price : $50

At a glance

  • Originator Panacos Pharmaceuticals Inc
  • Class Small molecules
  • Mechanism of Action Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 03 Apr 2009 Programmes for the development of second- and third-generation maturation inhibitors is ongoing in the US
  • 14 May 2007 Panacos has extended its medicinal chemistry contract with Evotec into its fourth year
  • 15 Mar 2005 Panacos Pharmaceuticals has been acquired and merged into V.I. Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top